Abstract
Investigations of clinical biomarkers for discovering a preclinical Alzheimer's disease (AD) remain behind those of CSF and PET biomarkers. Almost all of today's checklists for early detection of AD are not generally useful for recognizing preclinical AD. Conversely, activities of daily living or language ability should be evaluated. In addition, focusing on risk factors for onset of AD, such as living alone/social isolation, hearing loss, hyposmia, loss of teeth, body weight changes, apathy/depression, and their combination, is valuable for the clinical investigation of preclinical AD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
